{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-178950","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.912121+00:00","generated_at":"2026-05-17T14:44:22.996614+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Erasca Q2 2025 net loss $33.9M; cash $386.7M; INDs cleared for two RAS drugs","bullets":["Net loss of $33.9M ($0.12/sh) for Q2 2025, down from $63.2M ($0.29/sh) in Q2 2024.","Cash, equivalents, and marketable securities $386.7M as of June 30, 2025; expected to fund operations into H2 2028.","IND cleared for pan-KRAS inhibitor ERAS-4001 (Jun 2025) and pan-RAS molecular glue ERAS-0015 (May 2025); Phase 1 trials ongoing.","Initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 expected in 2026.","R&D expenses $21.2M in Q2 2025 vs $33.0M in Q2 2024, driven by lower impairment and personnel costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-178950","json":"https://secwatch.observer/filing/0001193125-25-178950.json","markdown":"https://secwatch.observer/filing/0001193125-25-178950.md","text":"https://secwatch.observer/filing/0001193125-25-178950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000119312525178950/0001193125-25-178950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000119312525178950/eras-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:44:22.996614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}